292 related articles for article (PubMed ID: 31577769)
1. Plasma metabolite profiling reveals potential biomarkers of giant cell tumor of bone by using NMR-based metabolic profiles: A cross-sectional study.
Wang W; Liu X; Wu J; Kang X; Xie Q; Sheng J; Xu W; Liu D; Zheng W
Medicine (Baltimore); 2019 Oct; 98(40):e17445. PubMed ID: 31577769
[TBL] [Abstract][Full Text] [Related]
2. Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles.
Wang W; Yang GJ; Zhang J; Chen C; Jia ZY; Li J; Xu WD
Arthritis Res Ther; 2016 Oct; 18(1):244. PubMed ID: 27770826
[TBL] [Abstract][Full Text] [Related]
3. Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.
Zhong L; Zhang JP; Nuermaimaiti AG; Yunusi KX
Eur Rev Med Pharmacol Sci; 2014; 18(23):3673-80. PubMed ID: 25535139
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors.
Chen S; Li C; Wu B; Zhang C; Liu C; Lin X; Wu X; Sun L; Liu C; Chen B; Zhong Z; Xu L; Li E
Int J Oncol; 2014 Sep; 45(3):1133-42. PubMed ID: 24969034
[TBL] [Abstract][Full Text] [Related]
6. STAT1, IGF1, RAC1, and MDM2 Are Associated with Recurrence of Giant Cell Tumor of Bone.
Chen S; Du Z; Wu B; Shen H; Liu C; Qiu X; Zhang Y; Xu L; Li E; Zhong Z
J Immunol Res; 2018; 2018():4564328. PubMed ID: 29651441
[TBL] [Abstract][Full Text] [Related]
7. [Factors related to biologic behavior in giant cell tumor of bone].
Ran XY; Huang J; Zhang HZ; Jiang ZM; Chen J
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):669-74. PubMed ID: 24433729
[TBL] [Abstract][Full Text] [Related]
8. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
9. The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location.
Scotto di Carlo F; Divisato G; Iacoangeli M; Esposito T; Gianfrancesco F
BMC Cancer; 2018 Apr; 18(1):358. PubMed ID: 29609578
[TBL] [Abstract][Full Text] [Related]
10. Characterization of MicroRNA Expression Profiles in Patients with Giant Cell Tumor.
Qin S; He NB; Yan HL; Dong Y
Orthop Surg; 2016 May; 8(2):212-9. PubMed ID: 27384730
[TBL] [Abstract][Full Text] [Related]
11. Plasma-metabolite-biomarkers for the therapeutic response in depressed patients by the traditional Chinese medicine formula Xiaoyaosan: A (1)H NMR-based metabolomics approach.
Liu CC; Wu YF; Feng GM; Gao XX; Zhou YZ; Hou WJ; Qin XM; Du GH; Tian JS
J Affect Disord; 2015 Oct; 185():156-63. PubMed ID: 26186531
[TBL] [Abstract][Full Text] [Related]
12. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
13. Expression of bone morphogenetic proteins in giant cell tumor of bone.
Kudo N; Ogose A; Ariizumi T; Kawashima H; Hotta T; Hatano H; Morita T; Nagata M; Siki Y; Kawai A; Hotta Y; Hoshino M; Endo N
Anticancer Res; 2009 Jun; 29(6):2219-25. PubMed ID: 19528484
[TBL] [Abstract][Full Text] [Related]
14. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
[TBL] [Abstract][Full Text] [Related]
15. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
[TBL] [Abstract][Full Text] [Related]
16. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis.
Jung J; Kim SH; Lee HS; Choi GS; Jung YS; Ryu DH; Park HS; Hwang GS
Clin Exp Allergy; 2013 Apr; 43(4):425-33. PubMed ID: 23517038
[TBL] [Abstract][Full Text] [Related]
17. TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone.
Wang T; Jiao J; Zhang H; Zhou W; Li Z; Han S; Wang J; Yang X; Huang Q; Wu Z; Yan W; Xiao J
Int J Cancer; 2017 Oct; 141(8):1630-1642. PubMed ID: 28670703
[TBL] [Abstract][Full Text] [Related]
18. A short-term in vivo model for giant cell tumor of bone.
Balke M; Neumann A; Szuhai K; Agelopoulos K; August C; Gosheger G; Hogendoorn PC; Athanasou N; Buerger H; Hagedorn M
BMC Cancer; 2011 Jun; 11():241. PubMed ID: 21668953
[TBL] [Abstract][Full Text] [Related]
19. Giant cell tumor of bone.
Amanatullah DF; Clark TR; Lopez MJ; Borys D; Tamurian RM
Orthopedics; 2014 Feb; 37(2):112-20. PubMed ID: 24679193
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
